MorphoSys provides update on current status and coming development in 2009

26 January 2009

Munich, Germany-based synthetic antibody specialist MorphoSys has updated investors on its planned developments for 2009, particularly in  its partnered antibody pipeline.

"MorphoSys is ideally positioned to advance its pipeline in 2009," said  chief executive Simon Moroney. "We have a solid financial foundation,  plus a proven technology and promising targets, which together give us  the means of building a very strong proprietary drug pipeline. Even in  this challenging economic climate, MorphoSys is ideally positioned to  build value by advancing its pipeline, while maintaining profitability,"  he added.

"Snapshot" of the end of 2009

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight